MiRNA-based Lifespan extension therapy: RNF2 (ring finger protein 2) prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 2/June/2014, 11.02 pm

MiRNA-based Lifespan extension therapy: RNF2 (ring finger protein 2) prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 2/June/2014, 11.02 pm

MiRNA-based Lifespan extension therapy: RNF2 (ring finger protein 2) prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 2/June/2014, 11.02 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., MiRNA-based Lifespan extension therapy: RNF2 (ring finger protein 2) prolongs  mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 2/June/2014, 11.02 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Significance: It has been shown earlier that angiotensin II type I receptor (AT1R) antagonist prolongs mammalian life span. This study suggests, for the first time, that  RNF2 (ring finger protein 2) , by decreasing the expression of its target gene,  it may suppress the expression of AT1R. And, thereby, it may (1) decrease blood pressure; and (2) and extend the lifespan of an individual. Thus, pharmacological formulations encompassing RNF2 (ring finger protein 2) activators may be used to extend the life-span of an individual.

Undisclosed information: How RNF2 (ring finger protein 2)  suppresses the expression of  angiotensin II type I receptor (AT1R)